{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.42","value":"10120"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"The AUC0-180 is a measure of the plasma concentration of rituximab over time. The AUC0-180 was calculated in micrograms per millilitres times day (mcg/mL\\*day).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received rituximab as an intravenous (IV) infusion of 375 milligrams per meter squared (mg/m\\^2) once a week on Days 1, 8, 15 and 22 during the Remission Induction Phase (Day 1 (baseline) to Month 6) and were followed for a minimum of 18 months (maximum 4.5yrs) during the Follow-up Phase until the Common-closeout (CCO))","id":"OG000","title":"Rituximab (Experimental)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis population included all participants in the safety population who provided at least one evaluable PK sample.","reportingStatus":"POSTED","timeFrame":"From Day 1 to Day 180","title":"Pharmacokinetics: Area Under the Concentration-Time Curve From Time 0 to 180 Days (AUC-180) of Rituximab","type":"SECONDARY","unitOfMeasure":"mcg/mL*day"}